|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Turning Point Therapeutics, Inc. (TPTX) |
|
|
$76.01 0.00 (0.00%) as of 4:30 Tue 8/16
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
48,170,000 |
Market
Cap: |
3.66(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$76.01 - $76.01 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cui Jingrong Jean |
Chief Scientific Officer |
|
2020-01-27 |
4 |
AS |
$56.82 |
$403,652 |
I/I |
(7,000) |
862,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2020-01-15 |
4 |
AS |
$53.03 |
$610,853 |
I/I |
(11,500) |
869,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2020-01-14 |
4 |
AS |
$52.44 |
$990,811 |
I/I |
(18,500) |
880,719 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2020-01-13 |
4 |
AS |
$52.49 |
$978,073 |
I/I |
(18,500) |
899,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2020-01-10 |
4 |
AS |
$54.00 |
$1,067,161 |
I/I |
(18,500) |
917,719 |
|
- |
|
Cui Jingrong Jean |
Director |
|
2019-12-30 |
4 |
OE |
$5.12 |
$86,344 |
I/I |
16,864 |
890,383 |
|
- |
|
Cui Jingrong Jean |
Director |
|
2019-12-27 |
4 |
OE |
$3.20 |
$179,456 |
I/I |
38,080 |
873,519 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-20 |
4 |
AS |
$62.64 |
$729,150 |
I/I |
(11,500) |
936,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-19 |
4 |
AS |
$59.84 |
$1,130,257 |
I/I |
(18,500) |
947,719 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-18 |
4 |
AS |
$57.76 |
$1,095,170 |
I/I |
(18,500) |
966,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-17 |
4 |
AS |
$60.30 |
$1,134,374 |
I/I |
(18,500) |
984,719 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-16 |
4 |
AS |
$55.45 |
$671,077 |
I/I |
(11,500) |
1,003,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-13 |
4 |
AS |
$55.43 |
$641,169 |
I/I |
(11,500) |
1,014,719 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-12 |
4 |
AS |
$53.18 |
$622,291 |
I/I |
(11,500) |
1,026,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-11 |
4 |
AS |
$52.72 |
$608,787 |
I/I |
(11,500) |
1,037,719 |
|
- |
|
Baker Brian Lee |
VP of Finance and Admin. |
|
2019-12-10 |
4 |
A |
$31.13 |
$6,723 |
D/D |
216 |
3,016 |
|
- |
|
Countouriotis Athena |
President & CEO |
|
2019-12-10 |
4 |
A |
$31.13 |
$21,976 |
D/D |
706 |
22,706 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-10 |
4 |
AS |
$53.79 |
$627,631 |
I/I |
(11,500) |
1,049,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-09 |
4 |
AS |
$54.33 |
$636,229 |
I/I |
(11,500) |
1,060,719 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-06 |
4 |
AS |
$50.67 |
$2,583,588 |
I/I |
(50,890) |
1,072,219 |
|
- |
|
Cui Jingrong Jean |
Chief Scientific Officer |
|
2019-12-05 |
4 |
AS |
$50.93 |
$2,914,936 |
I/I |
(56,110) |
1,123,109 |
|
- |
|
Glaxosmithkline Plc |
Director |
|
2019-09-10 |
4 |
B |
$45.00 |
$7,999,965 |
I/I |
177,777 |
2,170,327 |
2.1 |
- |
|
Countouriotis Athena |
President & CEO |
|
2019-09-10 |
4 |
B |
$45.00 |
$450,000 |
D/D |
10,000 |
22,000 |
2.81 |
- |
|
Larson Yi |
EVP & Chief Financial Officer |
|
2019-09-10 |
4 |
B |
$45.00 |
$99,990 |
D/D |
2,222 |
2,222 |
2.74 |
- |
|
George Simeon |
Director |
|
2019-09-10 |
4 |
B |
$45.00 |
$7,999,965 |
I/I |
177,777 |
2,170,327 |
2.1 |
- |
|
142 Records found
|
|
Page 5 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|